Teva launches generic Letairis
Teva is debuting generic Letairis (ambrisentan) tablets, in 5 mg and 10 mg dosage strengths.
Ambrisentan is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension to improve exercise ability and delay clinical worsening. In combination with tadalafil, ambrisentan is indicated to reduce the risks of disease progression and hospitalization for worsening pulmonary arterial hypertension and to improve exercise ability.
For all female patients, ambrisentan tablets are only available through a restricted program called the Ambrisentan Risk Evaluation & Mitigation Strategy due to the risk of fetal harm.
“The launch of ambrisentan tablets in the U.S. is an important addition to Teva’s growing generic portfolio of nearly 60 cardiovascular medicines,” Teva executive vice president and head of North America commercial Brendan O’Grady said. “Our ability to help treat this disease is a testament to our commitment to providing affordable, generic treatment options to people living with chronic, life-long conditions.”
Letairis had a market value of nearly $247 million as of February 2019, according to IQVIA data.
Ambrisentan is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension to improve exercise ability and delay clinical worsening. In combination with tadalafil, ambrisentan is indicated to reduce the risks of disease progression and hospitalization for worsening pulmonary arterial hypertension and to improve exercise ability.
For all female patients, ambrisentan tablets are only available through a restricted program called the Ambrisentan Risk Evaluation & Mitigation Strategy due to the risk of fetal harm.
“The launch of ambrisentan tablets in the U.S. is an important addition to Teva’s growing generic portfolio of nearly 60 cardiovascular medicines,” Teva executive vice president and head of North America commercial Brendan O’Grady said. “Our ability to help treat this disease is a testament to our commitment to providing affordable, generic treatment options to people living with chronic, life-long conditions.”
Letairis had a market value of nearly $247 million as of February 2019, according to IQVIA data.